A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT07365319, led by Eikon Therapeutics with Merck Sharp & Dohme, and recruiting on the registry. Official title: A Global, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008). Planned enrolment is 750 participants (estimated). The study started in 2026-06-15 and primary completion is expected in 2035-12-31. No results have been posted on ClinicalTrials.gov.